FDA Approves Four Updated COVID-19 Vaccines for the 2026–2027 Season

The Food and Drug Administration (FDA) has granted approval for four revised COVID-19 vaccines intended for the 2026–2027 season, specifically targeting the JN.1-lineage XFG variant. This decision aims to enhance protection against the most prevalent strain of the virus as we approach the colder months.

The newly approved vaccines are available for adults aged 65 and older, as well as for younger individuals who have underlying health conditions that heighten their risk of severe COVID-19. The eligibility criteria vary slightly depending on the specific vaccine.

These updated vaccines, developed by prominent pharmaceutical companies including Moderna, Novavax-Sanofi, and Pfizer-BioNTech, are designed to provide immunity against the COVID-19 variants that are currently circulating. With the fall and winter seasons approaching, health officials emphasize the importance of receiving the vaccine to ensure better protection during this time of year.

### Overview of the Approved Vaccines

The four vaccines that have received FDA approval include:

– **COMIRNATY (Pfizer-BioNTech):** Approved for individuals aged 5 and older with underlying health conditions, as well as for all adults 65 and older.
– **SPIKEVAX (Moderna):** Approved for those aged 6 months and older with underlying health conditions, along with all adults 65 and older.
– **MNEXSPIKE (Moderna):** Approved for individuals aged 12 and older with underlying health conditions, and all adults 65 and older.
– **NUVAXOVID (Novavax):** Approved for those aged 12 and older with underlying health conditions, and all adults 65 and older.

COMIRNATY, SPIKEVAX, and MNEXSPIKE utilize mRNA technology, while NUVAXOVID is based on a protein subunit approach.

### The Importance of Updated Vaccines

Updated vaccines are crucial as they respond to the evolving nature of the virus. Dr. Monica Gandhi, a professor of medicine at the University of California, San Francisco, explains that the SARS-CoV-2 virus is highly adaptive, necessitating annual updates to vaccines for optimal effectiveness. This practice is similar to the seasonal updates for influenza vaccines, which also adjust to align with the most prevalent strains.

Dr. William Schaffner, an infectious disease expert at Vanderbilt University, points out that the rapid adaptability of mRNA technology allows for timely modifications to the vaccines, which can significantly reduce the risk of severe illness.

As of late August, the Centers for Disease Control and Prevention (CDC) reported rising COVID-19 cases in nearly every state, underscoring the urgent need for vaccination.

### Understanding the XFG Variant

The XFG variant, part of the Omicron family, is notable for its high transmissibility but does not appear to cause more severe illness than other variants. Experts highlight that while it spread rapidly during the summer, it remains crucial to monitor its impact on public health.

### Who Should Get Vaccinated?

The updated vaccines are recommended for all individuals aged 65 and older due to their higher risk of severe illness. Additionally, those with specific underlying health conditions—such as chronic kidney disease, chronic lung disease, heart conditions, diabetes, obesity, liver disease, and pregnant individuals—are also encouraged to get vaccinated. Furthermore, individuals who are in close contact with high-risk groups should